Eli Lilly Pens $1.5B Pact With Regor For Metabolic Disease Therapies

Eli Lilly And Co LLY is making a $1.5 billion biobucks bet on Chinese biotech Regor Therapeutics to develop new therapies for metabolic disorders.

  • Under the deal, Lilly will have a license to select Regor IP with an option to extend the license. 
  • Lilly will be responsible for clinical development, manufacturing, and commercialization worldwide except China, Macau, Hong Kong, and Taiwan, where Regor will maintain these rights and responsibilities.
  • Regor will receive an upfront payment of up to $50 million, which partially includes an equity investment by Lilly in Regor. 
  • The Company is also eligible to receive up to $1.5 billion in potential milestone payments and tiered royalties from low-single to low-double digits.
  • Also Read: Lilly's COVID-19 Antibody Cocktail Scores FDA Emergency Use For Kids, Including Newborns.
  • Price Action: LLY shares are up 0.45% at $244.00 during the premarket session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareContractsGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!